Abstract:BackgroundHigh expression of ubiquitin ligase MDM2 is a primary cause of p53 inactivation in many tumors, making it a promising therapeutic target. However, MDM2 inhibitors have failed in clinical trials due to p53-induced feedback that enhances MDM2 expression. This underscores the urgent need to find an effective adaptive genotype or combination of targets.MethodsKinome-wide CRISPR/Cas9 knockout screen was performed to identify genes that modulate the response to MDM2 inhibitor using TP53 wild type cancer cells and found ULK1 as a candidate. The MTT cell viability assay, flow cytometry and LDH assay were conducted to evaluate the activation of pyroptosis and the synthetic lethality effects of combining ULK1 depletion with p53 activation. Dual-luciferase reporter assay and ChIP-qPCR were performed to confirm that p53 directly mediates the transcription of GSDME and to identify the binding region of p53 in the promoter of GSDME. ULK1 knockout / overexpression cells were constructed to investigate the functional role of ULK1 both in vitro and in vivo. The mechanism of ULK1 depletion to activate GSMDE was mainly investigated by qPCR, western blot and ELISA.ResultsBy using high-throughput screening, we identified ULK1 as a synthetic lethal gene for the MDM2 inhibitor APG115. It was determined that deletion of ULK1 significantly increased the sensitivity, with cells undergoing typical pyroptosis. Mechanistically, p53 promote pyroptosis initiation by directly mediating GSDME transcription that induce basal-level pyroptosis. Moreover, ULK1 depletion reduces mitophagy, resulting in the accumulation of damaged mitochondria and subsequent increasing of reactive oxygen species (ROS). This in turn cleaves and activates GSDME via the NLRP3-Caspase inflammatory signaling axis. The molecular cascade makes ULK1 act as a crucial regulator of pyroptosis initiation mediated by p53 activation cells. Besides, mitophagy is enhanced in platinum-resistant tumors, and ULK1 depletion/p53 activation has a synergistic lethal effect on these tumors, inducing pyroptosis through GSDME directly.ConclusionOur research demonstrates that ULK1 deficiency can synergize with MDM2 inhibitors to induce pyroptosis. p53 plays a direct role in activating GSDME transcription, while ULK1 deficiency triggers upregulation of the ROS-NLRP3 signaling pathway, leading to GSDME cleavage and activation. These findings underscore the pivotal role of p53 in determining pyroptosis and provide new avenues for the clinical application of p53 restoration therapies, as well as suggesting potential combination strategies.

Deubiquitinating enzyme USP48 mediates pyroptosis and meliorates immune evasion in tumors by stabilizing GSDME expression

USP48 stabilizes gasdermin E to promote pyroptosis in cancer

USP18 Antagonizes Pyroptosis by Facilitating Selective Autophagic Degradation of Gasdermin D

Transcription factor Sp1 transcriptionally enhances GSDME expression for pyroptosis

Gasdermin-mediated Pyroptosis Confers Anticancer Immunity

The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles

Synthetic Lethality of Combined ULK1 Defection and P53 Restoration Induce Pyroptosis by Directly Upregulating GSDME Transcription and Cleavage Activation Through ROS/NLRP3 Signaling

The Role of Cell Pyroptosis Mediated by GSDMs in Antitumor Immunity

Pyroptosis, metabolism, and tumor immune microenvironment

The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants

E3 Ubiquitin Ligase SYVN1 is a Key Positive Regulator for GSDMD-mediated Pyroptosis

The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment

Crosstalk of HDAC4, PP1, and GSDMD in controlling pyroptosis

Chemotherapeutic Drugs-Induced Pyroptosis Mediated by Gasdermin E Promotes the Progression and Chemoresistance of Pancreatic Cancer

Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade

Loss of Deubiquitylase USP2 Triggers Development of Glioblastoma Via TGF-β Signaling.

Mechanism and regulation of pyroptosis-mediated in cancer cell death

USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1

The Deubiquitinase USP22 Regulates PD-L1 Degradation in Human Cancer Cells.

Pyroptosis-related gene GSDMC indicates poor prognosis and promotes tumor progression by activating the AKT/mTOR pathway in lung squamous cell carcinoma

Epithelial-Mesenchymal Transition Induces GSDME Transcriptional Activation for Inflammatory Pyroptosis